MedTrace Logo

Neuropeptide Treatment for Hot Flushes During the Menopause

NCT02668185 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2021-05-03

Study results available
· View outcomes & findings →

Summary

Placebo-controlled, double-blinded, cross-over clinical trial of a new investigational product

Conditions

  • Menopausal Flushing

Interventions

DRUG

NK3R antagonist - AZD4901

Neurokinin 3 receptor antagonist

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Medical Research Council

    collaborator OTHER_GOV

  • AstraZeneca

    collaborator INDUSTRY

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • Imperial College London

    lead OTHER

Principal Investigators

  • Waljit S Dhillo, MBBS PhD · Imperial College and NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
62 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2017-01-01
Completion
2017-01-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02668185 on ClinicalTrials.gov